دورية أكاديمية
Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case.
| العنوان: | Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case. |
|---|---|
| المؤلفون: | Schönthal AH; Departments of1Molecular Microbiology and Immunology., Swenson S; 2Neurological Surgery, and., Bonney PA; 2Neurological Surgery, and., Wagle N; 3Pacific Brain Tumor Center, Pacific Neuroscience Institute, Santa Monica, California; and., Simmon VF; 4NeOnc Technologies, Inc., Los Angeles, California., Mathew AJ; 5Pathology, and., Hurth KM; 5Pathology, and., Chen TC; 2Neurological Surgery, and.; 4NeOnc Technologies, Inc., Los Angeles, California.; 6USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California. |
| المصدر: | Journal of neurosurgery. Case lessons [J Neurosurg Case Lessons] 2022 Aug 22; Vol. 4 (8). Date of Electronic Publication: 2022 Aug 22 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association of Neurosurgeons dba Journal of Neurosurgery Publishing Group Country of Publication: United States NLM ID: 9918227275606676 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 2694-1902 (Electronic) Linking ISSN: 26941902 NLM ISO Abbreviation: J Neurosurg Case Lessons Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Charlottesville, VA] : American Association of Neurosurgeons dba Journal of Neurosurgery Publishing Group, [2021]- |
| مستخلص: | Background: Intranasal delivery of NEO100, a pharmaceutical-grade version of the natural monoterpene perillyl alcohol (POH), is undergoing clinical phase IIa testing as a treatment for glioblastoma (GBM). However, so far there is no evidence that intranasal delivery of NEO100 indeed results in POH reaching intracranial malignancies in a patient. Observations: After surgical removal of her recurrent GBM tumor, a patient received daily intranasal NEO100 therapy for more than 3 years before a second recurrence emerged. At that time, a final dose of NEO100 was given shortly before the tumor tissue was surgically removed, and the tissue was processed for high-performance liquid chromatography analysis of POH and its primary metabolite, perillic acid (PA). Both molecules could readily be detected in the tumor tissue. Lessons: This is the first demonstration of POH and PA in brain tumor tissue from any patient. It reveals that intranasal administration of NEO100 is a valid approach to achieve delivery of this agent to a brain tumor. In view of the noninvasive and safe nature of this method, along with tentative indications of activity, our findings add confidence to the notion that intranasal administration of NEO100 holds potential as a new treatment option for brain-localized malignancies. |
| References: | Neuro Oncol. 2022 Nov 2;24(11):1989-2000. (PMID: 35460555) Int J Mol Sci. 2018 Dec 06;19(12):. (PMID: 30563210) Mol Cancer Ther. 2012 Nov;11(11):2462-72. (PMID: 22933703) Sci Rep. 2021 Mar 18;11(1):6351. (PMID: 33737566) Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895) Am J Cancer Res. 2015 Apr 15;5(5):1580-93. (PMID: 26175929) Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. (PMID: 33392507) Carcinogenesis. 2019 Nov 25;40(11):1299-1307. (PMID: 31504231) Radiol Oncol. 2018 Jun 06;52(2):121-128. (PMID: 30018514) J Pharmacol Exp Ther. 2004 Nov;311(2):568-75. (PMID: 15210838) Anticancer Res. 2013 Dec;33(12):5625-31. (PMID: 24324108) Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7. (PMID: 18295834) Mol Cancer. 2015 May 15;14:105. (PMID: 25976744) J Neurooncol. 2016 Aug;129(1):147-54. (PMID: 27270908) Clin Cancer Res. 2000 Aug;6(8):3071-80. (PMID: 10955786) Expert Rev Anticancer Ther. 2020 Sep;20(9):785-795. (PMID: 32799576) Mol Cell Biochem. 2016 Jan;411(1-2):307-15. (PMID: 26475687) Cancer Lett. 2007 Nov 18;257(2):216-26. (PMID: 17888568) Clin Cancer Res. 2013 Feb 15;19(4):764-72. (PMID: 23209033) Pharmacol Res. 2015 Jan;91:69-77. (PMID: 25497898) J Clin Oncol. 1990 Jul;8(7):1277-80. (PMID: 2358840) Jpn J Clin Oncol. 2021 Jan 1;51(1):45-53. (PMID: 32888020) J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676) Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931) Neurooncol Adv. 2021 Feb 12;3(1):vdab005. (PMID: 33604574) Drug Deliv Transl Res. 2022 Apr;12(4):735-757. (PMID: 33491126) |
| فهرسة مساهمة: | Keywords: blood-brain barrier; case report; monoterpene; recurrent glioblastoma |
| تواريخ الأحداث: | Date Created: 20220911 Latest Revision: 20221202 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9706323 |
| DOI: | 10.3171/CASE22215 |
| PMID: | 36088606 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2694-1902 |
|---|---|
| DOI: | 10.3171/CASE22215 |